||Recombinant human CD5L cDNA (20 – 347 aa, derived from BC033586) fused with T7-His-TEV cleavage site Tag (29aa) at N-terminal was expressed in E. coli.
||0.5 mg/ml, sterile-filtered, in 20 mM pH 8.0 Tris-HCl Buffer, with proprietary formulation of NaCl, KCl, EDTA, arginine, DTT and Glycerol.
||MASMTGGQQMGRGHHHHHHENLYFQGGEFSPSGVRLVGGLHRCEGRVEVEQKGQWGTVCDDGWDIKDVAVLCREL GCGAASGTPSGILYEPPAEKEQKVLIQSVSCTGTEDTLAQCEQEEVYDCSHDEDAGASCENPESSFSPVPEGVRL ADGPGHCKGRVEVKHQNQWYTVCQTGWSLRAAKVVCRQLGCGRAVLTQKRCNKHAYGRKPIWLSQMSCSGREATL QDCPSGPWGKNTCNHDEDTWVECEDPFDLRLVGGDNLCSGRLEVLHKGVWGSVCDDNWGEKEDQVVCKQLGCGKS LSPSFRDRKCYGPGVGRIWLDNVRCSGEEQSLEQCQHRFWGFHDCTHQEDVAVICSG
||>90% by SDS-PAGE
||1. May be used for in vitro non-glycosylated CD5L protein mediated lipolytic pathway regulation study with this protein as either coating matrix protein or as soluble factor.2. May be used for CD5L protein – protein interaction assay.3. May be used as enzymatic substrate for various proteases.4. Potential diagnostic and therapeutic target protein for controlling obesity disease.5. May be used for specific antibody production.
||Keep at -80centigrade for long term storage. Product is stable at 4 centigrade for at least 30 days.